| |SEPTEMBER 20258ASTRAZENECA'S TAGRISSO SETS RECORD IN EGFR LUNG CANCERMERIL LAUNCHES MIZZO ENDO 4000 ROBOTIC SURGERY SYSTEMMeril which is a medical device company from India that is one of the best in the world, has introduced the Mizzo Endo 4000, an advanced soft tissue robotic surgical system of the next generation, and this is a great step in the direction of India being a leader in MedTech worldwide.The Mizzo Endo 4000 that has been made for precision and versatility is a product of AI-driven 3D anatomical mapping, 5G-enabled telesurgery capabilities, and an open-console design. The said system can be used for a wide range of surgical specialties such as general surgery, gynecology, urology, thoracic, ENT, oncology, and a lot more and thus it is a truly multi-specialty, future-ready platform.Surgeons in India now for the first time are able to carry out real-time remote surgeries. As a result, expert care can be accessed in places where there is a lack of the same. DICOM-based pre-visualization, audio-visual feedback robotic arms, and a Universal Visit Cart are some of the advanced features that not only contribute to the accuracy of surgery but also the availability of it for training purposes.Vivek Shah, CEO, Meril, stated, "This system is constructed to provide safer, minimally invasive procedures, with a rapid recovery, and the outcomes are also improved." "Over time, we foresee it totally revolutionizing India's healthcare and putting the country on the global map of tech-driven surgical solutions," he added.Meril's dedication to the goal of providing health care of the highest standard at affordable and scalable levels, despite the challenges, is demonstrated by the Mizzo Endo 4000, which was introduced at the time of India's increasing emphasis on healthcare self-sufficiency and digital innovation. Meril keeps on crossing her limits on global deliveries of healthcare with the commitment she made to the planet and life in more than 150 countries. POTOP STORIESAstraZeneca has announced today landmark data from the Phase III FLAURA2 trial, demonstrating that its targeted therapy, Tagrisso (osimertinib), plus pemetrexed and platinum-based chemotherapy, achieved the longest overall survival reported in any global Phase III study for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).The final data, presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, showed a median overall survival (OS) of 47.5 months--nearly 4 years--for the Tagrisso, pemetrexed, and platinum-based chemotherapy combination.The OS for Tagrisso monotherapy was 37.6 months. This represents a major breakthrough compared to the standard survival established by the original FLAURA trial, which established Tagrisso as the first-line standard of care.David Planchard, MD, PhD, Thoracic Oncologist at Gustave Roussy Institute of Oncology in Villejuif, France, and principal investigator of the trial, said: "The fundamental goals of lung cancer treatment are to extend survival while preserving patients' quality of life...With two highly effective options, physicians can better tailor treatment to individual patient needs and maximize outcomes."Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, said, "The FLAURA2 final analysis sets a new survival benchmark in EGFR-mutated advanced lung cancer, with Tagrisso plus chemotherapy extending median overall ... of non-small cell lung cancer. These results reinforce Tagrisso's role as the backbone of treatment in EGFR-mutated lung cancer."With these landmark data, Tagrisso continues to establish itself as a global standard of care and an important backbone for subsequent treatment approaches in advanced lung cancer. PO
< Page 7 | Page 9 >